VendorMark said:The GIP arm is doing real work rather than padding the label.
I read this differently from VendorMark, on substance rather than tone. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.
If somebody has the primary source to hand I would rather cite it than paraphrase it.